Regeneron Pharmaceuticals is seeing a modest reset in fair value estimates, with one updated model lifting the figure ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

New clinical data reinforce Dupixent’s role in treating eosinophilic esophagitis and may support its long-term positioning in ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children ...

FDA approves Dupixent ® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis In the pivotal trial, more than twice as many children achieved ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

Five years after its first FDA approval in eczema, Sanofi’s Dupixent is still blazing a trail in inflammatory diseases. That’s the evaluation of Bill Sibold, Sanofi’s global head of specialty care, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

For the second consecutive month, Dupixent finished as the leader among the top 10 Rx and over-the-counter brands. The eczema and asthma drug from Sanofi and Regeneron had an impressions share of ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

DUBLIN--(BUSINESS WIRE)--The "Dupixent - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Dupixent - Drug Insight, 2019 report provides comprehensive information of the ...